Elsevier

Metabolism

Volume 52, Issue 2, February 2003, Pages 163-167
Metabolism

Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes*,**

https://doi.org/10.1053/meta.2003.50035Get rights and content

Abstract

A time-delayed fluorescence immunoassay was developed for the determination of serum levels of methylglyoxal (MG)-derived hydroimidazolone using a monoclonal antiserum raised against Nα-acetyl-Nδ-(5-hydro-5-methyl)-4-imidazolone, Europium-labeled anti-mouse IgG antiserum as indicator, and MG modified bovine serum albumin (BSA) as standard. Serum levels of hydroimidazolone were measured in 45 patients with type 2 diabetes aged 59.4 ± 6.1 (mean ± SD) years and with duration of diabetes of 7.3 ± 3.1 years, and in 19 nondiabetic controls aged 56.3 ± 4.3 years. The serum levels of hydroimidazolone were significantly higher in patients compared to controls: median, 3.0 (5-95 percentile, 1.6 to 5.4) U/mg protein versus 1.9 (1.2 to 2.8) U/mg protein (P =.0005). Significant positive correlations were observed between the serum levels of hydroimidazolone and serum levels of advanced glycation end products (AGEs), measured with a polyclonal anti-AGE antibody: r = 0.59 for patients (P <.0001), and r = 0.65 for controls (P =.002). Similarly, significant correlations were also found between serum levels of hydroimidazolone and Nϵ-(carboxymethyl)-lysine (CML): r = 0.36 in patients and r = 0.55 for controls (both P =.02). Serum hydroimidazolone levels did not correlate with fasting plasma glucose or hemoglobin A1c (HbA1c) levels. The observed differences between patients with diabetes and nondiabetic controls seem to be comparable to differences measured for other AGE compounds. Copyright 2003, Elsevier Science (USA). All rights reserved.

References (41)

  • FA Shamsi et al.

    Immunological evidence for methylglyoxal-derived modifications in vivo

    J Biol Chem

    (1998)
  • T Niwa et al.

    Imidazolone, a novel advanced glycation end product, is present at high levels in kidneys of rats with streptozotocin-induced diabetes

    FEBS Letters

    (1997)
  • EA Abordo et al.

    Synthesis and secretion of tumour necrosis factor–α by human monocytic THP-1 cells and chemotaxis induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation endproducts

    Immunol Lett

    (1997)
  • DA Greene et al.

    Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications

    N Engl J Med

    (1987)
  • JW Baynes et al.

    Role of oxidative stress in diabetic complications. A new perspective on an old paradigm

    Diabetes

    (1999)
  • D Koya et al.

    Protein kinase C activation and the development of diabetic complications

    Diabetes

    (1998)
  • M Brownlee

    Glycation and diabetic complications

    Diabetes

    (1994)
  • SM Haffner et al.

    Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

    N Engl J Med

    (1998)
  • IM Stratton et al.

    Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study

    BMJ

    (2000)
  • M Brownlee et al.

    Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications

    N Engl J Med

    (1988)
  • Cited by (160)

    View all citing articles on Scopus
    *

    Supported by grants from the Norwegian Foundation for Health and Rehabilitation, Aker Diabetes Research Fund, and the Norwegian Diabetes Association, and in part by a grant from the National Institutes of Health, Bethesda, MD.

    **

    Address reprint requestst to Bente K. Kilhovd, MD, Aker Diabetes Research Centre, Aker University Hospital, N-0514 Oslo, Norway.

    View full text